Organon to acquire Dermavant for $1.2bn, expanding its presence in immuno-dermatology
Organon, a global healthcare company focused on women’s health, has announced a definitive agreement to acquire Dermavant Sciences Ltd., a Roivant company specialising in immuno-dermatology, ... Read More
Organon and Eli Lilly expand global reach of migraine treatment Emgality
Organon and Eli Lilly and Company have expanded their commercialization agreement for Emgality, a leading migraine treatment, into 11 additional markets, reinforcing their commitment to ... Read More
Organon, Samsung Bioepis launch HUMIRA biosimilar HADLIMA in US
Organon & Co. and Samsung Bioepis revealed that HADLIMA (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab), is now accessible to patients in the United States. This ... Read More